Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | LBL-007 |
Trade Name | |
Synonyms | LBL007|LBL 007 |
Drug Descriptions |
LBL-007 targets LAG3 and prevents its interaction with MHC II molecules and liver sinusoidal endothelial cell lectin, potentially leading to relief of LAG-3 mediated immunosuppression and decreased tumor growth (PMID: 31242068). |
DrugClasses | LAG3 Antibody 18 |
CAS Registry Number | NA |
NCIT ID | C179260 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bevacizumab + Capecitabine + LBL-007 | Bevacizumab Capecitabine LBL-007 | 0 | 1 |
Bevacizumab + Capecitabine + LBL-007 + Tislelizumab | Bevacizumab Capecitabine LBL-007 Tislelizumab | 0 | 1 |
LBL-007 | LBL-007 | 0 | 0 |
LBL-007 + Toripalimab | LBL-007 Toripalimab | 0 | 0 |
LBL-007 + unspecified PD-1 antibody | LBL-007 unspecified PD-1 antibody | 0 | 0 |